September 2026 Monthly Content Release Notes Copied

09/24/20262026 ContentContent releasePhysician, Clinical, Admin, Billing

Inference Groups

Summary

This release includes updates to the prognostic documentation for Prostate Cancer.

Additions

Artera AI risk score: Added to the Prognostic Details section for Prostate Cancer.

Removals

OncotypeDX: Removed from the Prognostic Details section for Prostate Cancer.
Prolaris: Removed from the Prognostic Details section for Prostate Cancer.

Lab Analytes & Panels

Summary

This release includes 15 newly created panels and 17 newly created analytes. Two existing panels were updated, and 4 existing analytes were updated.

Additions

11-Desoxycortisol panel
AChR binding Abs, serum panel
Anticoagulant medication neutralization
Cortisol, free 24 Hr urine w/creatinine panel
Cyclospora smear, stool
Cyclospora smear, stool panel
Cyclospora smear, stool source
DCISionRT by preludeDx panel
FIB-4 panel
Fibrinogen genetic analysis panel
FoundationOne MRD panel
GM1 IgG Autoantibodies
GM1 IgG autoantibody panel
Hexagonal phospholipid confirmation, sec
IgA heavy light chains, serum panel
IgA K/L HLC ratio
IgA Kappa, mg/L
IgA Lambda, mg/L
JAK2 V617F digital PCR panel
Myeloma MRD flow analysis
Myeloma MRD flow comment
Myeloma MRD flow immunophenotyping
Myeloma MRD flow MRD population
Myeloma MRD flow results
NeoTYPE AML prognostic profile (plus FLT3 by PCR) panel
NeoTYPE MDS/CMML profile (plus FLT3 by PCR) panel
Neutralized dRVVT screen ratio
Rheumatoid arthritis IgM, IU/mL
Tetanus IgG Abs, IU/mL
TT Mix+TTN
Von willebrand factor GPIbM activity, %
Von willebrand factor GPlbM activity panel

Updates

AChR binding Abs, serum, nmol/L
Desoxycortisol (Compound S), S
LabCorp OmniSeq INSIGHT panel
Lupus anticoagulant panel
Thrombin neutralization
Thrombin time mix

Medications

Summary

Added new investigational medications and updated research medication content to support clinical trials.

Additions

Arcotatug Tavatecan invest (IBI343 invest IV)
Pelabresib invest (DAK539, CPI-0610 invest Oral)
Setidegrasib invest (ASP3082 invest IV)
SYS6043 invest (SYS6043 invest IV)

Updates

Medications	Updates
Aromasin (exemestane oral) Tamoxifen Oral	Updated Form: Removed values for Duration and Refill Added Duration of 30 days
AVZO-1418 invest IV	New SIG available: 0 mg/kg AIBW intravenously once
BG-C477 invest IV	New Unit of Measure available: mg/kg AIBW New Quick SIG PICK available: 0 mg/kg AIBW intravenously once 2.7 mg/kg AIBW intravenously once 3.3 mg/kg AIBW intravenously once
Exemestane Oral	Default Dispense Amount and Day-Supply: 30
FMC-376 invest Oral	New Form available: 100 mg tablet (also for Research) 250 mg tablet (also for Research)
GSK5764227 invest IV	New Name available: Risvutatug Rezetecan invest (Ris-Rez; GSK5764227 invest IV)
NEOK002 invest IV	Updated Form available: 100 mg recon soln (also for Research)
PF-07248144 invest Oral	New Alias available: Prifetrastat invest
Posfrea (Palonosetron IV)	New SIG available: Palonosetron 0.075 mg intravenously Push once; administer over 10 seconds; Administer over 10 seconds immediately before the induction of anesthesia Palonosetron 0.25 mg intravenously Push once; administer over 30 seconds; Administer over 30 seconds approximately 30 minutes prior to start of chemotherapy SIG suppressed: Palonosetron 0.25 mg intravenously Push once; administer 30 minutes prior to start of chemotherapy over 30 secs. Palonosetron 0 mg/kg intravenously As Directed.
Rasonque (daraxonrasib Oral)	New SIG available: 150 mg orally daily 200 mg orally daily New Maximum Single Dose available: 400 mg
Tamoxifen Oral	Default Dispense Amount and Day-Supply: 30

Regimens

Summary

Introduced 10 new oncology regimens and updated content across multiple disease areas.

Additions

Regimen Name	Diagnosis
BCG (TICE) (Intravesicular) + Durvalumab Q84D (Induction) fb Maintenance Q84D	Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer
Daratumumab SQ + Iberdomide + Dexamethasone Q28D	Multiple Myeloma (MM)
Daraxonrasib Q30D	Pancreatic Cancer
Denileukin Diftitox Q21D	Lymphoma, Non-Hodgkin (NHL); Mycosis Fungoides/Sezary Syndrome; Primary Cutaneous Lymphoma, Other
Gedatolisib D1,8,15 + Fulvestrant Q28D	Breast Cancer
Gedatolisib D1,8,15 + Palbociclib D1-21 + Fulvestrant Q28D	Breast Cancer
Leuprolide, Goserelin, or Triptorelin GnRH Fertility Preservation Q28days	All Problems
Influenza Vaccines 2026-2027	All Problems
Mitomycin Intravesicular (Zusduri)	Bladder Cancer; Renal Pelvis and Ureter Cancer; Urethral Cancer
Zidesamtinib Q30D	Lung Cancer, Non-small Cell (NSCLC)

Updates

All Problems
Anal Cancer
Bladder Cancer
Breast Cancer
Cervical Cancer
Esophageal Cancer
Fallopian Tube Cancer
Gastric Cancer
Head and Neck Cancer
Leukemia, Chronic Lymphocytic (CLL)
Leukemia, Chronic Myeloid (CML)
Lung Cancer, Non-small Cell (NSCLC)
Lung Cancer, Small Cell
Lymphoma, Non-Hodgkin (NHL)
Melanoma, Skin
Multiple Myeloma (MM)
Myelofibrosis
Ovarian and Primary Peritoneal Cancer
Polycythemia Vera
Prostate Cancer
Renal Pelvis and Ureter Cancer
Sarcoma, Bone
Sarcoma, Soft Tissue
Urethral Cancer
Uterine Cancer

Renames

BEFORE Reference Name	AFTER Reference Name
Mitomycin (Intravesicular)	Mitomycin (Intravesicular) Aqueous Solution
Pertuzumab IV + Trastuzumab IV Q21D Maintenance (following non-TCH regimens)	Pertuzumab IV + Trastuzumab IV Q21D Maintenance (following TCH or non-TCH regimens)

Billing & HCPCS

Summary

Terminology and coding updates for new medications, including biosimilars and quarterly CMS HCPCS updates.

Updates

The September 2026 updates include new HCPCS Level II codes to separately identify products approved under the 505(b)(2) New Drug Application (NDA) or the Biologics License Applications (BLA) pathways after October 2003 and not rated as therapeutically equivalent to a reference listed product in an existing code. A complete application summary and coding link can be found on the CMS HCPCS Level II Coding Decisions page.

Please visit the CMS website for a complete list of October 2026 HCPCS Quarterly updates.

The following products have not been released per First Databank (FDB):

J3406 Inj omidubicel-onlv, tx dose
J9066 Inj bendamustine, avyxa 1mg
Q5173 Inj, denosumab-adet, 1 mg

Additions

Medication	HCPCS Codes
Gadoquatrane IV	A9579 per 1 mL
Garetosmab-grts IV	J3590 per 300 mg
Pegfilgrastim-unne Subcutaneous	Q5169 per 0.5 mg
Rusfertide Subcutaneous	J3490 per 41 mg
Vusolimogene oderparepvec-wtpg intratumoral	J9999 per 40 mPF unit
Zilganersen Intrathecal	J3490 per 58 mg

The following HCPCS codes will be effective October 1, 2026

Medication	HCPCS Codes
Cocaine Nasal Solution 4 %	J0014 per 1 mg
Delafloxacin IV	J3268 per 1 mg
Etoposide Intraventricular	J9186 per 1 mg
Etoposide Intraventricular	J9187 per 1 mg
Etoposide IV	J9186 per 1 mg
Etoposide IV	J9187 per 1 mg
Filgrastim-laha Continuous Subcutaneous Infusion	Q5172 per 1 mcg
Filgrastim-laha IV	Q5172 per 1 mcg
Filgrastim-laha Subcutaneous	Q5172 per 1 mcg
Fluorouracil continuous intra-arterial infusion	J9191 per 10 mg
Fluorouracil continuous intra-arterial infusion	J9192 per 10 mg
Fluorouracil IV	J9191 per 10 mg
Fluorouracil IV	J9192 per 10 mg
Fluorouracil oral	J9191 per 10 mg
Fluorouracil oral	J9192 per 10 mg
Furosemide Subcutaneous (Furoscix)	J1947 per 1 mg
Furosemide Subcutaneous (Lasix ONYU)	J1946 per 1 mg
Furosemide Subcutaneous Auto-Injector (Furoscix)	J1947 per 1 mg
Leucovorin IM	J0643 per 1 mg
Leucovorin IM	J0644 per 1 mg
Leucovorin IV	J0643 per 1 mg
Leucovorin IV	J0643 per 1 mg
Mycophenolate IV	J7526 per 5 mg
Mycophenolate Oral	J7524 per 5 mg
Mycophenolate Oral Suspension	J7529 per 5 mg
Mycophenolate Oral Suspension	J7530 per 5 mg
Mycophenolate Suspension via feeding tube	J7529 per 5 mg
Mycophenolate Suspension via feeding tube	J7530 per 5 mg
Pegzilarginase-nbln IV	J1818 per 0.05 mg
Pegzilarginase-nbln Subcutaneous	J1818 per 0.05 mg
Piflufolastat F 18 IV	A9613 per 1 mCi 37 MBq
Tividenofusp alfa-eknm IV	J1757 per 1 mg
Trabectedin IV	J9362 per 0.01 mg

Removals

The following HCPCS codes will be discontinued on September 30, 2026.

Medication	HCPCS Codes
Etoposide Intraventricular	J9181 per 10 mg
Etoposide IV	J9181 per 10 mg
Fluorouracil Continuous Intra-Arterial Infusion	J9190 per 500 mg
Fluorouracil IV	J9190 per 500 mg
Fluorouracil Oral	J9190 per 500 mg
furosemide Subcutaneous (Furoscix)	J1941 per 20 mg
furosemide Subcutaneous Auto-Injector (Furoscix)	J1941 per 20 mg
Leucovorin IM	J0640 per 50 mg
Leucovorin IV	J0640 per 50 mg
Mycophenolate IV	J7519 per 10 mg
Mycophenolate Oral	J7517 per 250 mg
Mycophenolate Oral Suspension	J7514 per 100 mg
Mycophenolate Oral Suspension	J7517 per 250 mg
Mycophenolate Oral Suspension	J7528 per 100 mg
Mycophenolate Suspension via feeding tube	J7514 per 100 mg
Mycophenolate Suspension via feeding tube	J7517 per 250 mg
Mycophenolate Suspension via feeding tube	J7528 per 100 mg
Trabectedin IV	J9352 per 0.1 mg

NDC – HCPCS Crosswalk

Updates

ASP pricing can be found on the CMS website.

Additions

Medication	HCPCS Codes	NDCs
Cocaine Nasal Solution 4 % (Goprelto)	J0014 per 1 mg	64950035904
Etoposide IV (Avopef)	J9186 per 1 mg	83831014405 83831014525
Etoposide Intraventricular (Avopef)	J9186 per 1 mg	83831014405 83831014525
Fluorouracil Continuous Intra-Arterial Infusion (Favlyxa)	J9191 per 10 mg	83831014301 83831016410
Fluorouracil IV (Favlyxa)	J9191 per 10 mg	83831014301 83831016410
Fluorouracil Oral (Favlyxa)	J9191 per 10 mg	83831014301 83831016410
Leucovorin IM (Vykoura)	J0644 per 1 mg	83831014705 83831014835 83831014950
Leucovorin IV (Vykoura)	J0644 per 1 mg	83831014705 83831014835 83831014950
Mycophenolate Oral Suspension (Myhibbin)	J7530 per 5 mg	24338001801
Mycophenolate Suspension via feeding tube (Myhibbin)	J7530 per 5 mg	24338001801
Piflufolastat F 18 IV (Pylarify)	A9613 per · 1 mCi · 37 MBq	85347000101
Filgrastim-laha continuous subcutaneous infusion (filkri)	Q5172 per 1 mcg	69448000803 69448000863 69448000903 69448000963
Filgrastim-laha IV (filkri)	Q5172 per 1 mcg	69448000803 69448000863 69448000903 69448000963
Filgrastim-laha IV (filkri)	Q5172 per 1 mcg	69448000803 69448000863 69448000903 69448000963
Furosemide subcutaneous (furoscix)	J1947 per 1 mg	71767010001
Furosemide subcutaneous (lasix ONYU)	J1946 per 1 mg	81137000115
Furosemide subcutaneous auto-injector (furoscix)	J1947 per 1 mg	71767011101
Pegfilgrastim-unne subcutaneous (armlupeg)	Q5169 per 0.5 mg	70748027301

Therapeutic Interchange Management

Summary

Details about recent content updates for Therapeutic Interchange Management content groups can be found on the Ontada Guide Site.